APO Research
Talk to an analyst

APO RESEARCH · REPORT

PD-1&PD-L1 Immunotherapy

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global PD-1&PD-L1 Immunotherapy Market Outlook and Growth Opportunities 2026

2 January 2026197 pages

Choose your research edition.

Industry ResearchPD-1&PD-L1 Immunotherapy Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal PD-1&PD-L1 Immunotherapy Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal PD-1&PD-L1 Immunotherapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal PD-1&PD-L1 Immunotherapy Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal PD-1&PD-L1 Immunotherapy Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global PD-1&PD-L1 Immunotherapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for PD-1&PD-L1 Immunotherapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the PD-1&PD-L1 Immunotherapy market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the PD-1&PD-L1 Immunotherapy market include Sanofi S.A., Novartis AG, Merck & Co., Inc., Eli Lilly & Company, Pfizer Inc., Jiangsu HengRui Medicine Co., Ltd., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc. and Innovent Biologics, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global PD-1&PD-L1 Immunotherapy market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of PD-1&PD-L1 Immunotherapy and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents PD-1&PD-L1 Immunotherapy sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the PD-1&PD-L1 Immunotherapy market size, projected growth trends, production technologies, key applications, and end-use industries.

PD-1&PD-L1 Immunotherapy Segment by Company

Sanofi S.A.

Novartis AG

Merck & Co., Inc.

Eli Lilly & Company

Pfizer Inc.

Jiangsu HengRui Medicine Co., Ltd.

GlaxoSmithKline plc

Regeneron Pharmaceuticals Inc.

Innovent Biologics, Inc.

F. Hoffmann-La Roche Ltd

Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

Bristol-Myers Squibb Company

BeiGene, Ltd.

AstraZeneca Plc

PD-1&PD-L1 Immunotherapy Segment by Type

PD-1 Inhibitors

PD-L1 Inhibitors

PD-1&PD-L1 Immunotherapy Segment by Application

Non-Small Cell Lung Cancer

Hepatocellular Carcinoma

Urothelial Carcinoma

Esophageal Cancer

Small Cell Lung Cancer

Others

PD-1&PD-L1 Immunotherapy Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global PD-1&PD-L1 Immunotherapy status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions PD-1&PD-L1 Immunotherapy market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify PD-1&PD-L1 Immunotherapy significant trends, drivers, influence factors in global and regions.

6. To analyze PD-1&PD-L1 Immunotherapy competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-1&PD-L1 Immunotherapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of PD-1&PD-L1 Immunotherapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-1&PD-L1 Immunotherapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the PD-1&PD-L1 Immunotherapy market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global PD-1&PD-L1 Immunotherapy industry.

Chapter 3: Detailed analysis of PD-1&PD-L1 Immunotherapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of PD-1&PD-L1 Immunotherapy in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of PD-1&PD-L1 Immunotherapy in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. PD-1&PD-L1 Immunotherapy Industry Trends Table 2. PD-1&PD-L1 Immunotherapy Industry Drivers Table 3. PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges Table 4. PD-1&PD-L1 Immunotherapy Industry Restraints Table 5. Global PD-1&PD-L1 Immunotherapy Revenue by Company (US$ Million) & (2021-2026) Table 6. Global PD-1&PD-L1 Immunotherapy Revenue Share by Company (2021-2026) Table 7. Global PD-1&PD-L1 Immunotherapy Sales Volume by Company (K Units) & (2021-2026) Table 8. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Company (2021-2026) Table 9. Global PD-1&PD-L1 Immunotherapy Average Price (US$/Unit) of Company (2021-2026) Table 10. Global PD-1&PD-L1 Immunotherapy Company Ranking, (2024-2026) & (USD Million) Table 11. Global PD-1&PD-L1 Immunotherapy Key Company Manufacturing Base & Headquarters Table 12. Global PD-1&PD-L1 Immunotherapy Company, Product Type & Application Table 13. Global PD-1&PD-L1 Immunotherapy Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global PD-1&PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PD-1 Inhibitors Table 18. Significant Companies of PD-L1 Inhibitors Table 19. Global PD-1&PD-L1 Immunotherapy Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global PD-1&PD-L1 Immunotherapy Sales Volume by Type (2021-2026) & (K Units) Table 21. Global PD-1&PD-L1 Immunotherapy Sales Volume by Type (2027-2032) & (K Units) Table 22. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Type (2021-2026) Table 23. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Type (2027-2032) Table 24. Global PD-1&PD-L1 Immunotherapy Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global PD-1&PD-L1 Immunotherapy Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global PD-1&PD-L1 Immunotherapy Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Type (2021-2026) Table 28. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Non-Small Cell Lung Cancer Table 30. Significant Companies of Hepatocellular Carcinoma Table 31. Significant Companies of Urothelial Carcinoma Table 32. Significant Companies of Esophageal Cancer Table 33. Significant Companies of Small Cell Lung Cancer Table 34. Significant Companies of Others Table 35. Global PD-1&PD-L1 Immunotherapy Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global PD-1&PD-L1 Immunotherapy Sales Volume by Application (2021-2026) & (K Units) Table 37. Global PD-1&PD-L1 Immunotherapy Sales Volume by Application (2027-2032) & (K Units) Table 38. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Application (2021-2026) Table 39. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Application (2027-2032) Table 40. Global PD-1&PD-L1 Immunotherapy Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global PD-1&PD-L1 Immunotherapy Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global PD-1&PD-L1 Immunotherapy Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Application (2021-2026) Table 44. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Application (2027-2032) Table 45. Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2026) & (K Units) Table 47. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2021-2026) Table 48. Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032) & (K Units) Table 49. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region (2027-2032) Table 50. Global PD-1&PD-L1 Immunotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global PD-1&PD-L1 Immunotherapy Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Region (2021-2026) Table 53. Global PD-1&PD-L1 Immunotherapy Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Region (2027-2032) Table 55. Global PD-1&PD-L1 Immunotherapy Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global PD-1&PD-L1 Immunotherapy Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global PD-1&PD-L1 Immunotherapy Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026) & (K Units) Table 60. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2021-2026) Table 61. Global PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032) & (K Units) Table 62. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Country (2027-2032) Table 63. Global PD-1&PD-L1 Immunotherapy Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global PD-1&PD-L1 Immunotherapy Sales Value Market Share by Country (2021-2026) Table 65. Global PD-1&PD-L1 Immunotherapy Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global PD-1&PD-L1 Immunotherapy Sales Value Market Share by Country (2027-2032) Table 67. Sanofi S.A. Company Information Table 68. Sanofi S.A. Business Overview Table 69. Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio Table 71. Sanofi S.A. Recent Development Table 72. Novartis AG Company Information Table 73. Novartis AG Business Overview Table 74. Novartis AG PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio Table 76. Novartis AG Recent Development Table 77. Merck & Co., Inc. Company Information Table 78. Merck & Co., Inc. Business Overview Table 79. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 81. Merck & Co., Inc. Recent Development Table 82. Eli Lilly & Company Company Information Table 83. Eli Lilly & Company Business Overview Table 84. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 86. Eli Lilly & Company Recent Development Table 87. Pfizer Inc. Company Information Table 88. Pfizer Inc. Business Overview Table 89. Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 91. Pfizer Inc. Recent Development Table 92. Jiangsu HengRui Medicine Co., Ltd. Company Information Table 93. Jiangsu HengRui Medicine Co., Ltd. Business Overview Table 94. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 96. Jiangsu HengRui Medicine Co., Ltd. Recent Development Table 97. GlaxoSmithKline plc Company Information Table 98. GlaxoSmithKline plc Business Overview Table 99. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 101. GlaxoSmithKline plc Recent Development Table 102. Regeneron Pharmaceuticals Inc. Company Information Table 103. Regeneron Pharmaceuticals Inc. Business Overview Table 104. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 106. Regeneron Pharmaceuticals Inc. Recent Development Table 107. Innovent Biologics, Inc. Company Information Table 108. Innovent Biologics, Inc. Business Overview Table 109. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio Table 111. Innovent Biologics, Inc. Recent Development Table 112. F. Hoffmann-La Roche Ltd Company Information Table 113. F. Hoffmann-La Roche Ltd Business Overview Table 114. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio Table 116. F. Hoffmann-La Roche Ltd Recent Development Table 117. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information Table 118. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview Table 119. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 121. Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Development Table 122. Bristol-Myers Squibb Company Company Information Table 123. Bristol-Myers Squibb Company Business Overview Table 124. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio Table 126. Bristol-Myers Squibb Company Recent Development Table 127. BeiGene, Ltd. Company Information Table 128. BeiGene, Ltd. Business Overview Table 129. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio Table 131. BeiGene, Ltd. Recent Development Table 132. AstraZeneca Plc Company Information Table 133. AstraZeneca Plc Business Overview Table 134. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio Table 136. AstraZeneca Plc Recent Development Table 137. Key Raw Materials Table 138. Raw Materials Key Suppliers Table 139. PD-1&PD-L1 Immunotherapy Distributors List Table 140. PD-1&PD-L1 Immunotherapy Customers List Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. PD-1&PD-L1 Immunotherapy Product Image Figure 2. Global PD-1&PD-L1 Immunotherapy Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global PD-1&PD-L1 Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 4. Global PD-1&PD-L1 Immunotherapy Sales (2021-2032) & (K Units) Figure 5. Global PD-1&PD-L1 Immunotherapy Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global PD-1&PD-L1 Immunotherapy Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PD-1 Inhibitors Image Figure 10. PD-L1 Inhibitors Image Figure 11. Global PD-1&PD-L1 Immunotherapy Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global PD-1&PD-L1 Immunotherapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Type (2021-2032) Figure 14. Global PD-1&PD-L1 Immunotherapy Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global PD-1&PD-L1 Immunotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Type (2021-2032) Figure 17. Non-Small Cell Lung Cancer Image Figure 18. Hepatocellular Carcinoma Image Figure 19. Urothelial Carcinoma Image Figure 20. Esophageal Cancer Image Figure 21. Small Cell Lung Cancer Image Figure 22. Others Image Figure 23. Global PD-1&PD-L1 Immunotherapy Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global PD-1&PD-L1 Immunotherapy Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Application (2021-2032) Figure 26. Global PD-1&PD-L1 Immunotherapy Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global PD-1&PD-L1 Immunotherapy Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Application (2021-2032) Figure 29. Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global PD-1&PD-L1 Immunotherapy Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global PD-1&PD-L1 Immunotherapy Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global PD-1&PD-L1 Immunotherapy Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America PD-1&PD-L1 Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 34. North America PD-1&PD-L1 Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe PD-1&PD-L1 Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 36. Europe PD-1&PD-L1 Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America PD-1&PD-L1 Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 40. South America PD-1&PD-L1 Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. PD-1&PD-L1 Immunotherapy Value Chain Figure 128. Manufacturing Cost Structure Figure 129. PD-1&PD-L1 Immunotherapy Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • PD-1 Inhibitors
  • PD-L1 Inhibitors
Applications
  • Non-Small Cell Lung Cancer
  • Hepatocellular Carcinoma
  • Urothelial Carcinoma
  • Esophageal Cancer
  • Small Cell Lung Cancer
  • Others
Companies covered
  • Sanofi S.A.
  • Novartis AG
  • Merck & Co., Inc.
  • Eli Lilly & Company
  • Pfizer Inc.
  • Jiangsu HengRui Medicine Co., Ltd.
  • GlaxoSmithKline plc
  • Regeneron Pharmaceuticals Inc.
  • Innovent Biologics, Inc.
  • F. Hoffmann-La Roche Ltd
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • Bristol-Myers Squibb Company
  • BeiGene, Ltd.
  • AstraZeneca Plc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global PD-1&PD-L1 Immunotherapy Sales Value (2021-2032)
  4. 1.2.2 Global PD-1&PD-L1 Immunotherapy Sales Volume (2021-2032)
  5. 1.2.3 Global PD-1&PD-L1 Immunotherapy Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 PD-1&PD-L1 Immunotherapy Market Dynamics
  1. 2.1 PD-1&PD-L1 Immunotherapy Industry Trends
  2. 2.2 PD-1&PD-L1 Immunotherapy Industry Drivers
  3. 2.3 PD-1&PD-L1 Immunotherapy Industry Opportunities and Challenges
  4. 2.4 PD-1&PD-L1 Immunotherapy Industry Restraints
3 PD-1&PD-L1 Immunotherapy Market by Company
  1. 3.1 Global PD-1&PD-L1 Immunotherapy Company Revenue Ranking in 2025
  2. 3.2 Global PD-1&PD-L1 Immunotherapy Revenue by Company (2021-2026)
  3. 3.3 Global PD-1&PD-L1 Immunotherapy Sales Volume by Company (2021-2026)
  4. 3.4 Global PD-1&PD-L1 Immunotherapy Average Price by Company (2021-2026)
  5. 3.5 Global PD-1&PD-L1 Immunotherapy Company Ranking (2024-2026)
  6. 3.6 Global PD-1&PD-L1 Immunotherapy Company Manufacturing Base and Headquarters
  7. 3.7 Global PD-1&PD-L1 Immunotherapy Company Product Type and Application
  8. 3.8 Global PD-1&PD-L1 Immunotherapy Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global PD-1&PD-L1 Immunotherapy Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 PD-1&PD-L1 Immunotherapy Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 PD-1&PD-L1 Immunotherapy Market by Type
  1. 4.1 PD-1&PD-L1 Immunotherapy Type Introduction
  2. 4.1.1 PD-1 Inhibitors
  3. 4.1.2 PD-L1 Inhibitors
  4. 4.2 Global PD-1&PD-L1 Immunotherapy Sales Volume by Type
  5. 4.2.1 Global PD-1&PD-L1 Immunotherapy Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global PD-1&PD-L1 Immunotherapy Sales Volume by Type (2021-2032)
  7. 4.2.3 Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Type (2021-2032)
  8. 4.3 Global PD-1&PD-L1 Immunotherapy Sales Value by Type
  9. 4.3.1 Global PD-1&PD-L1 Immunotherapy Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global PD-1&PD-L1 Immunotherapy Sales Value by Type (2021-2032)
  11. 4.3.3 Global PD-1&PD-L1 Immunotherapy Sales Value Share by Type (2021-2032)
5 PD-1&PD-L1 Immunotherapy Market by Application
  1. 5.1 PD-1&PD-L1 Immunotherapy Application Introduction
  2. 5.1.1 Non-Small Cell Lung Cancer
  3. 5.1.2 Hepatocellular Carcinoma
  4. 5.1.3 Urothelial Carcinoma
  5. 5.1.4 Esophageal Cancer
  6. 5.1.5 Small Cell Lung Cancer
  7. 5.1.6 Others
  8. 5.2 Global PD-1&PD-L1 Immunotherapy Sales Volume by Application
  9. 5.2.1 Global PD-1&PD-L1 Immunotherapy Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global PD-1&PD-L1 Immunotherapy Sales Volume by Application (2021-2032)
  11. 5.2.3 Global PD-1&PD-L1 Immunotherapy Sales Volume Share by Application (2021-2032)
  12. 5.3 Global PD-1&PD-L1 Immunotherapy Sales Value by Application
  13. 5.3.1 Global PD-1&PD-L1 Immunotherapy Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global PD-1&PD-L1 Immunotherapy Sales Value by Application (2021-2032)
  15. 5.3.3 Global PD-1&PD-L1 Immunotherapy Sales Value Share by Application (2021-2032)
6 PD-1&PD-L1 Immunotherapy Regional Sales and Value Analysis
  1. 6.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global PD-1&PD-L1 Immunotherapy Sales by Region (2021-2032)
  3. 6.2.1 Global PD-1&PD-L1 Immunotherapy Sales by Region: 2021-2026
  4. 6.2.2 Global PD-1&PD-L1 Immunotherapy Sales by Region (2027-2032)
  5. 6.3 Global PD-1&PD-L1 Immunotherapy Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global PD-1&PD-L1 Immunotherapy Sales Value by Region (2021-2032)
  7. 6.4.1 Global PD-1&PD-L1 Immunotherapy Sales Value by Region: 2021-2026
  8. 6.4.2 Global PD-1&PD-L1 Immunotherapy Sales Value by Region (2027-2032)
  9. 6.5 Global PD-1&PD-L1 Immunotherapy Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America PD-1&PD-L1 Immunotherapy Sales Value (2021-2032)
  12. 6.6.2 North America PD-1&PD-L1 Immunotherapy Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe PD-1&PD-L1 Immunotherapy Sales Value (2021-2032)
  15. 6.7.2 Europe PD-1&PD-L1 Immunotherapy Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific PD-1&PD-L1 Immunotherapy Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America PD-1&PD-L1 Immunotherapy Sales Value (2021-2032)
  21. 6.9.2 South America PD-1&PD-L1 Immunotherapy Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa PD-1&PD-L1 Immunotherapy Sales Value Share by Country, 2025 VS 2032
7 PD-1&PD-L1 Immunotherapy Country-level Sales and Value Analysis
  1. 7.1 Global PD-1&PD-L1 Immunotherapy Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global PD-1&PD-L1 Immunotherapy Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global PD-1&PD-L1 Immunotherapy Sales by Country (2021-2032)
  4. 7.3.1 Global PD-1&PD-L1 Immunotherapy Sales by Country (2021-2026)
  5. 7.3.2 Global PD-1&PD-L1 Immunotherapy Sales by Country (2027-2032)
  6. 7.4 Global PD-1&PD-L1 Immunotherapy Sales Value by Country (2021-2032)
  7. 7.4.1 Global PD-1&PD-L1 Immunotherapy Sales Value by Country (2021-2026)
  8. 7.4.2 Global PD-1&PD-L1 Immunotherapy Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt PD-1&PD-L1 Immunotherapy Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt PD-1&PD-L1 Immunotherapy Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt PD-1&PD-L1 Immunotherapy Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi S.A.
  2. 8.1.1 Sanofi S.A. Company Information
  3. 8.1.2 Sanofi S.A. Business Overview
  4. 8.1.3 Sanofi S.A. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi S.A. PD-1&PD-L1 Immunotherapy Product Portfolio
  6. 8.1.5 Sanofi S.A. Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG PD-1&PD-L1 Immunotherapy Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co., Inc.
  14. 8.3.1 Merck & Co., Inc. Company Information
  15. 8.3.2 Merck & Co., Inc. Business Overview
  16. 8.3.3 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  18. 8.3.5 Merck & Co., Inc. Recent Developments
  19. 8.4 Eli Lilly & Company
  20. 8.4.1 Eli Lilly & Company Company Information
  21. 8.4.2 Eli Lilly & Company Business Overview
  22. 8.4.3 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly & Company PD-1&PD-L1 Immunotherapy Product Portfolio
  24. 8.4.5 Eli Lilly & Company Recent Developments
  25. 8.5 Pfizer Inc.
  26. 8.5.1 Pfizer Inc. Company Information
  27. 8.5.2 Pfizer Inc. Business Overview
  28. 8.5.3 Pfizer Inc. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  30. 8.5.5 Pfizer Inc. Recent Developments
  31. 8.6 Jiangsu HengRui Medicine Co., Ltd.
  32. 8.6.1 Jiangsu HengRui Medicine Co., Ltd. Company Information
  33. 8.6.2 Jiangsu HengRui Medicine Co., Ltd. Business Overview
  34. 8.6.3 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu HengRui Medicine Co., Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  36. 8.6.5 Jiangsu HengRui Medicine Co., Ltd. Recent Developments
  37. 8.7 GlaxoSmithKline plc
  38. 8.7.1 GlaxoSmithKline plc Company Information
  39. 8.7.2 GlaxoSmithKline plc Business Overview
  40. 8.7.3 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline plc PD-1&PD-L1 Immunotherapy Product Portfolio
  42. 8.7.5 GlaxoSmithKline plc Recent Developments
  43. 8.8 Regeneron Pharmaceuticals Inc.
  44. 8.8.1 Regeneron Pharmaceuticals Inc. Company Information
  45. 8.8.2 Regeneron Pharmaceuticals Inc. Business Overview
  46. 8.8.3 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Regeneron Pharmaceuticals Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  48. 8.8.5 Regeneron Pharmaceuticals Inc. Recent Developments
  49. 8.9 Innovent Biologics, Inc.
  50. 8.9.1 Innovent Biologics, Inc. Company Information
  51. 8.9.2 Innovent Biologics, Inc. Business Overview
  52. 8.9.3 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Innovent Biologics, Inc. PD-1&PD-L1 Immunotherapy Product Portfolio
  54. 8.9.5 Innovent Biologics, Inc. Recent Developments
  55. 8.10 F. Hoffmann-La Roche Ltd
  56. 8.10.1 F. Hoffmann-La Roche Ltd Company Information
  57. 8.10.2 F. Hoffmann-La Roche Ltd Business Overview
  58. 8.10.3 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 F. Hoffmann-La Roche Ltd PD-1&PD-L1 Immunotherapy Product Portfolio
  60. 8.10.5 F. Hoffmann-La Roche Ltd Recent Developments
  61. 8.11 Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  62. 8.11.1 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Company Information
  63. 8.11.2 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Business Overview
  64. 8.11.3 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  66. 8.11.5 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. Recent Developments
  67. 8.12 Bristol-Myers Squibb Company
  68. 8.12.1 Bristol-Myers Squibb Company Company Information
  69. 8.12.2 Bristol-Myers Squibb Company Business Overview
  70. 8.12.3 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb Company PD-1&PD-L1 Immunotherapy Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Company Recent Developments
  73. 8.13 BeiGene, Ltd.
  74. 8.13.1 BeiGene, Ltd. Company Information
  75. 8.13.2 BeiGene, Ltd. Business Overview
  76. 8.13.3 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 BeiGene, Ltd. PD-1&PD-L1 Immunotherapy Product Portfolio
  78. 8.13.5 BeiGene, Ltd. Recent Developments
  79. 8.14 AstraZeneca Plc
  80. 8.14.1 AstraZeneca Plc Company Information
  81. 8.14.2 AstraZeneca Plc Business Overview
  82. 8.14.3 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca Plc PD-1&PD-L1 Immunotherapy Product Portfolio
  84. 8.14.5 AstraZeneca Plc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 PD-1&PD-L1 Immunotherapy Value Chain Analysis
  2. 9.1.1 PD-1&PD-L1 Immunotherapy Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 PD-1&PD-L1 Immunotherapy Sales Mode & Process
  6. 9.2 PD-1&PD-L1 Immunotherapy Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 PD-1&PD-L1 Immunotherapy Distributors
  9. 9.2.3 PD-1&PD-L1 Immunotherapy Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst